

FOR IMMEDIATE RELEASE

Media Contact:

Phil Rose, Chief Operating Officer
(859) 487-9858
letstalk@epmtherapeutics.com

epm Therapeutics Announces the Appointment of Kylie O’Keefe to its Board of Directors

This marks a key step toward transitioning the development of EPM301 from preclinical to clinical as a potential new therapy for Prader-Willi syndrome (PWS)

FLORENCE, Ky. – EPM Group Inc. a preclinical-stage biotechnology company doing business as (dba) epm Therapeutics, is pleased to announce the appointment of Kylie O’Keefe to its Board of Directors.

Dr. Peter Welburn, CEO of epm Therapeutics, commented: “With the positive outcome of our recent pre-IND meeting with the FDA and the formalization of our plans to enter the clinic, we recognized the need to bring talent and experience in rare disease drug development to our Board. Kylie will help guide us through the clinical phase of development of our lead program in Prader-Willi syndrome (PWS) and prepare us to maximize the commercial potential.”

Kylie is an accomplished business leader with broad biopharmaceutical experience and a proven track record in development and commercialization of products for rare diseases. Kylie is currently Chief Customer and Strategy Officer for uniQure. In this role, she leads the development and execution of uniQure’s global commercialization strategy. Her responsibilities include all commercial functions and medical affairs.

Most recently, she served as Chief Commercial Officer at PTC Therapeutics, where she led global commercial strategy, operations, and portfolio management for multiple rare neurology and metabolic commercial products across more than 50 countries. During her tenure, Ms. O’Keefe led several strategically significant commercial launches and supported corporate strategy and pipeline development for both small molecules and gene therapies. Earlier in her career, Ms. O’Keefe held key roles at LEO Pharma, where she launched a portfolio of pharmaceutical products in more than 30 countries.

Ms. O’Keefe holds a Bachelor’s degree in Biotechnology Innovation from Queensland University of Technology in Brisbane, Australia, and a graduate diploma in Managing Medical Product Innovation from Copenhagen Business School in Frederiksberg, Denmark.

Kylie commented: “Prader-Willi syndrome places an extraordinary daily burden on patients, families, and caregivers, and the need for safe, effective therapies remains of importance. I am proud to join the team at [EPM Therapeutics](http://www.epmtherapeutics.com) and stand alongside the broader PWS community

in advancing the potential of EPM301 as a meaningful new treatment option for people living with Prader-Willi syndrome.”

About epm Therapeutics

EPM Group, Inc., doing business as epm Therapeutics, is a privately held biotechnology company dedicated to the discovery and development of cannabinoid acid-based therapeutics for diseases with high unmet needs. Founded in 2017 in collaboration with Dr. Raphael Mechoulam, epm’s lead asset, EPM301, is a first-in-class oral therapy in development for the treatment of hyperphagia and other symptoms common in Prader-Willi syndrome. To learn more about epm, visit epmtherapeutics.com, or find us on [Facebook](#) and [LinkedIn](#).

About Prader-Willi Syndrome

Prader-Willi syndrome (PWS) is a genetic disorder with a birth incidence of approximately 1 in 15,000 live births. The syndrome arises from the loss of the paternally-inherited chromosome region 15q11-q13, referred to as the Prader-Willi syndrome critical region. This genetic defect results in damage to the hypothalamus, a critical brain region responsible for regulating essential functions such as hunger, sleep, and body temperature. PWS is characterized by severe hypotonia and a failure to thrive, followed by an intense preoccupation with food and hyperphagia (insatiable appetite) in early childhood. In addition to hyperphagia, individuals with PWS may also exhibit various neuropsychiatric symptoms and disorders, including temper outbursts, repetitive and ritualistic behaviors, inflexible thinking, skin picking, depression, and, in some cases, psychosis.

Forward-Looking Statements

This press release contains forward-looking statements regarding epm Therapeutics’ future operations, development plans, and potential market opportunities. All statements other than historical facts are forward-looking statements. Forward-looking statements involve risks and uncertainties, including the risk that the company may not receive required regulatory approvals, commercialize its product candidates, or realize the market potential of its pipeline. Actual results may differ materially.